Indegene Limited has informed the Exchange about Amalgamation/Merger
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene Limited's two step-down subsidiaries — Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (Canada) — have merged to form a new entity called Indegene Healthcare Canada Inc., effective January 1, 2026. Both subsidiaries were 100% held by Indegene, Inc. USA, which is in turn a wholly-owned subsidiary of the listed parent company. Combined projected revenue for FY25-26 is roughly CAD 6.78 million, with Trilogy contributing about CAD 5.4 million and Aptilon around CAD 1.38 million. No cash or share consideration was involved, and there is no change to Indegene Limited's shareholding pattern. The company has described the move as internal restructuring to streamline its North American operations, and the transaction qualifies as a related party deal done at arm's length.
This is a routine internal reorganization of wholly-owned subsidiaries with no change in ultimate control, no consideration paid, and no effect on the listed company's shareholding — so it's effectively neutral for shareholders.